Myriad Genetics has filed a patent for a laboratory execution system that automates laboratory processes. The system includes a centralized data management system and various components such as an automation system and an analytics results management system. The system can be used for complex analytical functions, including the detection of specific molecules of interest. The patent also describes a method for using the laboratory control system, which involves receiving a workflow process, performing operations on a sample, and generating a report based on the operations. GlobalData’s report on Myriad Genetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Myriad Genetics, Personalized medicine biomarkers was a key innovation area identified from patents. Myriad Genetics's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
A laboratory execution system for automating laboratory processes
A recently filed patent (Publication Number: US20230295716A1) describes a method for using a laboratory control system. The system includes an application module, an automation system, a SciComp module, and an analytics results management system (ARMS). The method involves receiving a workflow process through the application module, obtaining a sample container based on the workflow process using the automation system, performing operations on the sample using the SciComp module, and generating a report with the result using the ARMS.
The method also includes extracting components from the sample using a liquid handling apparatus, providing the report to a user device through the application module, and positioning the container at a destination location before performing the operations. The automation system interfaces with laboratory equipment using robotics units, and the SciComp module performs the operations using these units.
The sample in question can be whole blood, plasma, or serum from a subject with a history of cancer, and the extracted component is cell-free DNA (cfDNA). The operations on the sample involve enriching a DNA fraction of fragments containing tumor-specific somatic mutations. These mutations are determined by sequencing genomic DNA from a solid tumor sample and a non-tumor sample previously obtained from the subject.
The enrichment process can be hybrid capture-based, PCR-target enrichment, or on-sequencer enrichment. The method also includes detecting the presence or absence of DNA fragments containing the tumor-specific somatic mutations in the enriched DNA fraction. The detection sensitivity is about 20 to 50 ctDNA fragments per 500,000 cfDNA fragments.
Hybrid capture-based enrichment involves contacting the extracted cfDNA with oligonucleotides that can hybridize to the tumor-specific somatic mutations and selectively enriching the fragments that hybridize to the oligonucleotides. The plurality of oligonucleotides is capable of detecting at least 10 different tumor-specific somatic mutations.
The detection process can involve sequencing the DNA fragments, either through whole genome sequencing or targeted sequencing. The method also includes determining the fraction of cfDNA fragments that are circulating tumor DNA (ctDNA) fragments. The mutations in the tumor-specific somatic mutations can include SNPs, insertions, deletions, and translocations.
Additionally, the method allows for performing the operations on a second sample obtained from the subject at a later date to detect the presence or absence of DNA fragments containing any of the tumor-specific somatic mutations.
Overall, this patent describes a comprehensive method for using a laboratory control system to perform operations on samples, extract components, and detect tumor-specific somatic mutations in cell-free DNA. The method has potential applications in cancer diagnostics and monitoring.
To know more about GlobalData’s detailed insights on Myriad Genetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
